Cargando…

Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study

INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are believed to lower glucose levels and inhibit cardiovascular events related to type 2 diabetes (T2D). To maximize their benefits, the risk of resultant hypoglycemia has to be minimized; however, the magnitude of this risk remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horii, Takeshi, Oikawa, Yoichi, Kunisada, Narumi, Shimada, Akira, Atsuda, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703042/ https://www.ncbi.nlm.nih.gov/pubmed/33246930 http://dx.doi.org/10.1136/bmjdrc-2020-001856

Ejemplares similares

Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study
por: Horii, Takeshi, et al.
Publicado: (2021)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using (18)F-FDG PET/MRI
por: Rasul, Sazan, et al.
Publicado: (2020)

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
por: Gomez-Peralta, Fernando, et al.
Publicado: (2020)

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
por: Horii, Takeshi, et al.
Publicado: (2021)

Real‐world risk of lower‐limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score‐matched model analysis in Japan
por: Mizutani, Gen, et al.
Publicado: (2022)

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
por: Belfort-DeAguiar, Renata D., et al.
Publicado: (2015)

Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis
por: Jiao, Xiaojuan, et al.
Publicado: (2022)

Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
por: Klein, Klara R, et al.
Publicado: (2021)

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
por: Christiansen, Mark P, et al.
Publicado: (2021)

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
por: Kudo, Akihiro, et al.
Publicado: (2023)

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms
por: Riddy, Darren M, et al.
Publicado: (2021)

Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial
por: Wada, Eri, et al.
Publicado: (2020)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria
por: McGill, Janet B, et al.
Publicado: (2022)

Metformin and statin use associate with plasma protein N-glycosylation in people with type 2 diabetes
por: Singh, Sunny S, et al.
Publicado: (2020)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

Multilevel clustering approach driven by continuous glucose monitoring data for further classification of type 2 diabetes
por: Tao, Rui, et al.
Publicado: (2021)

Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial
por: Pittas, Anastassios G., et al.
Publicado: (2014)

Prediction of diabetic kidney disease with machine learning algorithms, upon the initial diagnosis of type 2 diabetes mellitus
por: Allen, Angier, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
por: Castellana, Marco, et al.
Publicado: (2020)

Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review
por: Raj, Rishi, et al.
Publicado: (2022)

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
por: Buse, John B, et al.
Publicado: (2023)

Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
por: Wang, Wei, et al.
Publicado: (2020)

Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
por: Novak, Vera, et al.
Publicado: (2014)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

KGF-2 and FGF-21 poloxamer 407 hydrogel coordinates inflammation and proliferation homeostasis to enhance wound repair of scalded skin in diabetic rats
por: Yang, Xuanxin, et al.
Publicado: (2020)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
por: Dailey, George, et al.
Publicado: (2019)

Time in range–A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study
por: Valenzano, Marina, et al.
Publicado: (2021)

Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation
por: Perraudeau, Fanny, et al.
Publicado: (2020)

Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study
por: Zhang, Xiaodan, et al.
Publicado: (2020)

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
por: Feng, Wenhuan, et al.
Publicado: (2021)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
por: Buse, John B, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_deeiilk3s6ncurtct9ttki817k